Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 101

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 101
---
 loss of patent rights in the relevant jurisdiction. Noncompliance
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond
to office actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In
such an event, Kadimastem’s competitors might be able to enter the market, which would have a material adverse effect on its business.

Kadimastem may not be able to enforce its intellectual property rights throughout the world.

Filing, prosecuting and defending
patents on product candidates in all countries throughout the world would be prohibitively expensive, and its intellectual property rights
in some countries outside the United States and Israel can be less extensive than those in the United States and Israel. In addition,
the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United States and Israel. Consequently,
Kadimastem may not be able to seek to prevent third parties from practicing its inventions in all countries outside the United States
and Israel, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors,
for example, may use Kadimastem’s technologies in jurisdictions where Kadimastem have not obtained patents to develop their own
products and further, may export otherwise infringing products to territories where it has patents, but enforcement is not as strong as
that in the United States and Israel.

Many companies have encountered
significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries,
particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual
property, particularly those relating to drug substances and product candidates and biopharmaceutical and biotechnology products, which
could make it difficult for Kadimastem to stop the infringement of its patents or marketing of competing products in violation of its
proprietary rights generally. To date, Kadimastem have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings
to enforce Kadimastem’s patent rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention
from other aspects of its business, could put its patents at risk of being invalidated or interpreted narrowly and its patent applications
at risk of not issuing and could provoke third parties to assert claims against Kadimastem. Kadimastem may not prevail in any lawsuits
that it initiates and the damages